All use cases · Persona 03 of 06

BD & Strategy Lead

"Should we license this? What does the comparator set actually look like?"

Engagement Discovery Diligence (one-shot)
Persona 03 / 04
— A scene from the deal room

The BD lead with three weeks to form a view on a Phase 2 asset.

The data room is open. The banker is friendly. The seller's narrative is, by construction, optimistic. The BD lead does not need a second narrative — she needs an independent reading of the regulatory path, the comparable set, and the deal terms that have actually closed in the indication.
“

Should we license this? What's the real regulatory timeline, and what does the comp set actually look like?

— a question we hear from BD & strategy teams during active diligence

What Brioche delivers

Independent diligence — written by people who do not represent the seller, the buyer, or the banker. A regulatory pathway read against precedent, a comparator set drawn from public filings, and a deal-terms context built from SEC disclosures and announced transactions.

  • Regulatory pathway A timeline drawn from precedent in the indication — not the seller's projection. Every BLA, NDA, CRL, and PDUFA date for analogous programs, with the rationale where public.
  • Comparator set Independently constructed. Programs the seller didn't mention. Endpoints where the asset is differentiated and endpoints where it isn't.
  • Deal precedent Announced terms in the indication and adjacent indications, sourced from SEC 10-K, 10-Q, and 8-K filings and press releases. Upfront / milestone / royalty splits where disclosed.
  • Format A diligence memo. A working session with the deal team. A list of the open questions worth pressing the seller on before close.
Illustrative scenario · not a real engagement Scenario sketch

A Phase 2 asset in a specialty indication being shopped for in-license — with a confident sponsor narrative and a noisy comparator landscape.

The BD lead has the CMC binder, the clinical data, and the seller's regulatory strategy memo. What she does not have is an independent read on whether the strategy is plausible against precedent, whether the comp set is honest, and what comparable in-licensing deals have closed at.

— Track 01

Pathway plausibility. Test the seller's proposed regulatory route against every precedent approval and CRL in the indication. Surface the assumptions the seller is making implicitly.

— Track 02

Honest comparator set. Independently construct the competitive landscape — including programs the seller's deck omits or underweights. Endpoints, dosing, patient population.

— Track 03

Deal-terms context. Pull comparable in-license transactions from 10-K and 8-K disclosures. Stage-matched, indication-adjacent. Where royalties or milestones are disclosed, surface them at the deal-team's elbow during negotiation.

Other use cases

How other teams use Brioche.

Clinical-stage CEOWill my IND get a CRL? Who is beating me to the indication?→Pharma R&D DirectorIs this target worth pursuing? What has already failed in this indication?→Regulatory Affairs HeadWhat deficiencies has FDA cited on similar submissions?→Precision medicine leadFor this patient with this mutation profile, what is the best-ranked therapeutic — and if nothing fits, what analog should we propose?→Investor diligenceA buy-side question on a target asset. Selectively, where the question is well-formed.→